Treatment of Junin Virus‐Infected Guinea Pigs With Immune Serum: Development of Late Neurological Disease

Guinea pigs infected with Argentine hemorrhagic fever virus (Junin) were treated with pooled, homologous convalescent sera. Use of 15,000 or 5,000 therapeutic units of immune sera prevented all signs of illness when administered within 24 hr of infection. We could also prevent illness and death in infected guinea pigs as late as 6 days after infection if we used more antisera (30,000 therapeutic units/ kg). In some treatment groups, surviving animals developed a late neurological syndrome with prominant rear‐limb paralysis. Treated animals typically expressed higher viral titers in the brain than in any other organ. There appeared to be no acute exacerbation of disease by antibody administration. Our data suggest that, after replicating peripherally, Junin virus infects the brain where circulating immunoglobulins may not eliminate viable virus. Subsequent replication of virus in the brain may generate a neurological phase of the illness. Histological examination of brains from guinea pigs in treatment groups favoring the neurological phase of illness showed encephalitis, meningitis, and swollen astrocytes, suggestive of neuronal degeneration. There is likely a delicate balance among presence of virus in the brain, the amount of antibody transported into the central nervous system, and the occurrence of this late neurological aspect of experimental Argentine hemorrhagic fever. Further study of this model may elucidate factors relevant in understanding the continuing problem of the late neurological syndrome seen in some human cases of Argentine hemorrhagic fever treated with immune plasma.

[1]  C. Peters,et al.  Cytolysis of Junin infected target cells by immune guinea pig spleen cells. , 1986, Microbial pathogenesis.

[2]  C. Peters,et al.  Effect of ribavirin and tributylribavirin on argentine hemorrhagic fever (Junin virus) in guinea pigs , 1986, Antimicrobial Agents and Chemotherapy.

[3]  J. Maiztegui,et al.  Experimental Argentine hemorrhagic fever in rhesus macaques: viral strain-dependent clinical response. , 1985, The Journal of infectious diseases.

[4]  C. Peters,et al.  Effect of immunosuppression on experimental Argentine hemorrhagic fever in guinea pigs , 1985, Journal of virology.

[5]  J. Maiztegui,et al.  IMPORTANCE OF DOSE OF NEUTRALISING ANTIBODIES IN TREATMENT OF ARGENTINE HAEMORRHAGIC FEVER WITH IMMUNE PLASMA , 1984, The Lancet.

[6]  J. Blejer,et al.  New attenuation marker for junin virus based on immunologic responses of guinea pigs. , 1982, The Journal of infectious diseases.

[7]  J. Maiztegui,et al.  EFFICACY OF IMMUNE PLASMA IN TREATMENT OF ARGENTINE HÆMORRHAGIC FEVER AND ASSOCIATION BETWEEN TREATMENT AND A LATE NEUROLOGICAL SYNDROME , 1979, The Lancet.

[8]  M. Weissenbacher,et al.  [Experimental Junin virus infection of guinea pigs. I. Pathological anatomy]. , 1976, Medicina.

[9]  H. F. Woods,et al.  AGE-DEPENDENT SENSITIVITY TO SALICYLATE , 1975, The Lancet.

[10]  K. Johnson,et al.  Measurement of Antibodies to Machupo Virus by the Indirect Fluorescent Technique , 1973, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[11]  K. Johnson,et al.  The Measurement of Specific Antibodies in Bolivian Hemorrhagic Fever by Neutralization of Virus Plaques , 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[12]  M. Weissenbacher,et al.  [Action of immune sera in experimental hemorrhagic fever]. , 1968, Medicina.

[13]  J. Maiztegui,et al.  [Late neurologic syndrome in patients with Argentinian hemorrhagic fever treated with immune plasma]. , 1985, Medicina.

[14]  R. Laguens,et al.  Junin virus infection of guinea pigs: immunohistochemical and ultrastructural studies of hemopoietic tissue. , 1981, The Journal of infectious diseases.

[15]  G. Eddy,et al.  Protection of monkeys against Machupo virus by the passive administration of Bolivian haemorrhagic fever immunoglobulin (human origin). , 1975, Bulletin of the World Health Organization.